Daily Anesthesiology Research Analysis
Analyzed 94 papers and selected 3 impactful papers.
Summary
Three notable studies in anesthesiology and critical care: a porcine randomized experiment shows ropivacaine-based regional anesthesia may protect muscle despite elevated compartment pressures in acute compartment syndrome; a nationwide Korean cohort quantifies a 55.6% 12‑month incidence of post‑intensive care syndrome and identifies high‑risk groups; and a randomized controlled trial demonstrates that adjunct intravenous esketamine after cesarean section reduces pain, inflammation, and early postoperative anxiety/depression without excess adverse effects.
Research Themes
- Regional anesthesia physiology and tissue protection in acute compartment syndrome
- Critical care survivorship and risk stratification for post-intensive care syndrome
- Perioperative multimodal analgesia affecting pain, mood, and inflammation after cesarean section
Selected Articles
1. Ropivacaine-Based Regional Anesthesia Exerts Muscle-Protective Effects Despite Elevated Compartment Pressure In A Porcine Model Of Acute Compartment Syndrome.
In a randomized porcine ACS model, ropivacaine-based regional anesthesia increased compartment pressure but improved regional metabolic markers (lower interstitial LDH and glucose) and reduced histologic muscle injury compared with placebo. Systemic hemodynamics and plasma biomarkers were similar between groups. These data suggest an early muscle-protective effect of regional anesthesia during evolving ACS.
Impact: This preclinical study challenges the prevailing concern that regional anesthesia may mask or worsen ACS by demonstrating biochemical and histological protection despite higher pressures. It provides a mechanistic basis to re-examine blanket contraindications to regional blocks in high-risk trauma.
Clinical Implications: In suspected or evolving ACS, regional anesthesia with ropivacaine might not exacerbate muscle ischemia and could confer short-term tissue protection; however, translation to human care requires cautious, protocolized monitoring and prospective clinical evaluation before practice change.
Key Findings
- Compartment pressure at T10 was higher with ropivacaine RA vs placebo (57.0 vs 41.5 mmHg; p=0.022), while MAP was similar.
- Interstitial injury markers were reduced with ropivacaine: c-LDH 24,475 vs 113,800 U/L (p=0.017) and c-glucose 19.5 vs 51.0 mg/dL (p=0.0043).
- Blinded histopathology showed attenuated degeneration and necrosis in the ropivacaine group; plasma biomarkers did not differ significantly.
Methodological Strengths
- Randomized allocation with continuous invasive monitoring of compartment pressure and MAP
- Multimodal assessment including interstitial microdialysis biomarkers and blinded histopathology
Limitations
- Preclinical porcine model with small sample size (N=20) and short observation window
- No functional outcomes or dose–response exploration; generalizability to human trauma uncertain
Future Directions: Prospective human studies to assess safety, perfusion/tissue biomarkers, pain control, and limb outcomes with regional anesthesia in suspected ACS; mechanistic work on neural–vascular interactions and dosing strategies.
BACKGROUND: Acute compartment syndrome (ACS) is a devastating sequela of orthopedic trauma characterized by elevated compartment pressure (CP) that precipitates tissue ischemia. The role of regional anesthesia (RA) in modulating these pathophysiological events remains controversial. This study investigated the impact of RA via ropivacaine 0.2% (RPVC) on CP, systemic hemodynamics, biochemical markers, and tissue integrity in a porcine model of ACS. METHODS: Twenty male pigs underwent ACS induction in the tibialis anterior compartment by targeted inflation of an angioplasty catheter and were randomized to receive either RPVC or placebo via a regional catheter. Continuous CP and mean arterial pressure (MAP) were recorded. Plasma samples (p-) and interstitial fluid (c-) were collected at predefined time points (T1, T3, T6, T8, T10) to quantify creatine kinase (CK), lactate (Lac), lactate dehydrogenase (LDH), and glucose (Gluc). Histopathological evaluation was performed at the end of the experiment (T10). RESULTS: At T10, CP was significantly elevated in the RPVC group [57.0 mmHg (49.0-59.0)] compared to placebo [41.5 mmHg (38.2-47.2); p=0.022], whereas MAP remained comparable (RPVC: 63.0 mmHg [58.0-65.0] vs. placebo: 59.0 mmHg [56.2-61.8]; p=0.13). Plasma biomarkers did not differ significantly (e.g., p-CK: RPVC 1940 U/l [868-3334] vs. placebo 1171 U/l [1020-1467]; p=0.24). In contrast, interstitial analysis demonstrated a marked reduction in tissue injury markers in the RPVC group, with c-LDH significantly lower [24475 U/l (19500-28213) vs. 113800 U/l (91000-116600); p=0.017] and c-Gluc substantially decreased [19.5 mg/dl (11.5-27.5) vs. 51.0 mg/dl (43.0-103.0); p=0.0043]. RPVC-treated tissue exhibited attenuated degeneration and reduced necrosis in a blinded histopathological scoring. CONCLUSIONS: Despite a higher CP, RPVC-based RA yielded an improved regional metabolic profile and mitigated tissue injury in ACS. These findings suggest a protective effect in the observed timeframe that merits further clinical exploration.
2. Post-intensive care syndrome after critical illness: incidence and predictors in a nationwide cohort.
Using a nationwide administrative cohort of 234,069 ICU survivors, the authors found a 12‑month PICS incidence of 55.6% after excluding prior diagnoses. Older age, female sex, socioeconomic disadvantage, baseline disability, comorbidities, and receipt of mechanical ventilation or CRRT independently increased risk. Physical impairments predominated, underscoring the need for structured survivorship programs.
Impact: This study provides robust, population-level incidence and risk estimates for PICS, enabling health systems to plan targeted post-ICU care and resource allocation.
Clinical Implications: Implement systematic screening for PICS domains within 12 months post-discharge, prioritize multidisciplinary rehabilitation for high-risk subsets, and integrate survivorship planning into ICU care pathways.
Key Findings
- PICS occurred in 55.6% (130,110/234,069) of ICU survivors within 12 months.
- Independent risk factors included older age, female sex, low income, pre-existing disability, cerebrovascular disease, dementia, chronic pulmonary disease.
- Exposure to mechanical ventilation (OR 1.40) and CRRT (OR 1.12) increased PICS risk; physical impairment was the most frequent domain.
Methodological Strengths
- Very large nationwide cohort with exclusion of prior PICS-related diagnoses to estimate incident cases
- Multivariable modeling across demographic, socioeconomic, comorbidity, and treatment exposures
Limitations
- Claims-based definitions risk misclassification and lack clinical granularity (e.g., standardized cognitive testing)
- Residual confounding and limited generalizability beyond the South Korean system
Future Directions: Prospective cohorts with standardized functional and neurocognitive assessments; randomized evaluations of post-ICU rehabilitation and risk-targeted interventions.
INTRODUCTION: As survival rates after critical illness improve, increasing numbers of ICU survivors experience post-intensive care syndrome (PICS), with physical, cognitive and psychiatric impairments. However, there is a lack of robust population-level estimates on incidence rates to guide the implementation of measures to address this issue. METHODS: We conducted a retrospective nationwide cohort study using the South Korean National Health Insurance Service database. Adults admitted to any ICU who were alive ≥ 12 months after hospital discharge were included. To estimate the incidence of PICS, we did not include patients with any PICS-related diagnosis in the year before the index ICU admission. Post-intensive care syndrome was defined as a new diagnosis in at least one domain - physical, cognitive or psychiatric - within 12 months of hospital discharge. RESULTS: Among 234,069 ICU survivors with no prior PICS diagnosis, 130,110 (55.6%) developed PICS within 12 months of hospital discharge. Risk factors included older age (odds ratio (OR) 1.01, 95%CI 1.01-1.01); female sex (OR 1.17, 95%CI 1.15-1.19); lower income, particularly among Medical Aid beneficiaries (OR 1.16, 95%CI 1.12-1.21); pre-existing disability (mild-to-moderate: OR 1.12; 95%CI 1.09-1.15; severe: OR 1.08, 95%CI 1.05-1.12); higher comorbidity burden such as cerebrovascular disease (OR 1.88, 95%CI 1.84-1.92), dementia (OR 3.11, 95%CI 2.91-3.31) or chronic pulmonary disease (OR 1.25, 95%CI 1.22-1.28); and exposure to mechanical ventilation (OR 1.40, 95%CI, 1.36-1.44) or continuous renal replacement therapy (OR 1.12, 95%CI 1.05-1.12). DISCUSSION: In a nationwide cohort of 234,069 ICU survivors, over half developed PICS within 12 months, with physical impairment most common. These findings quantify the survivorship burden attributable to critical illness and underpin the need for structured, multidisciplinary follow-up and rehabilitation for high-risk groups.
3. Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.
In a single-center randomized, blinded trial of 98 elective cesarean patients, adjunct intravenous esketamine reduced 24‑hour maximum pain scores, all assessed pain domains, delayed first PCIA demand, lowered CRP at 24 hours, and decreased rates of anxiety, depression, and sleep disorders on postoperative day 2, without increasing adverse effects or hyperalgesia.
Impact: This RCT supports esketamine as a multimodal adjunct that simultaneously addresses pain, inflammation, and early postoperative mood/sleep disturbances after cesarean section.
Clinical Implications: Consider esketamine as an adjunct to opioid-based PCIA in Enhanced Recovery After Cesarean pathways to improve analgesia and early psychological recovery, while monitoring for psychomimetic effects and tailoring dose to maternal/neonatal considerations.
Key Findings
- Esketamine reduced 24‑h maximum pain NRS (median 5 vs 6; P<0.0001) and lowered rest, visceral, and movement-related pain at all time points.
- Time to first PCIA compression was delayed and 24‑h CRP was lower with esketamine.
- Rates of postoperative day‑2 anxiety, depression, and sleep disorders were reduced; no significant differences in hyperalgesia or adverse effects.
Methodological Strengths
- Randomized, blinded, controlled design with trial registration
- Comprehensive outcomes including pain domains, inflammatory biomarker (CRP), and psychological measures
Limitations
- Single-center, modest sample size limits generalizability and precision for rare adverse events
- Short follow-up; psychological outcomes assessed only on postoperative day 2
Future Directions: Multicenter trials to validate dosing and safety, longer-term maternal mental health and breastfeeding outcomes, and mechanistic links between NMDA antagonism, inflammation, and recovery.
OBJECTIVE: Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. METHODS: This randomized, blinded, controlled trial enrolled single-term pregnant women scheduled for elective CS. This trial was a single-center study conducted at Chongqing University Fuling Hospital. A simple randomization method was used. SPSS version 26.0 generated random numbers. The participants were randomly included in the esketamine group (group E: intravenous esketamine 0.5 mg/kg + sufentanil 4 μg/kg followed by patient-controlled intravenous analgesia with esketamine 0.5 mg/kg) or the control group (C: normal saline + sufentanil 4 μg/kg PCIA). The primary outcome was the maximum pain numerical rating scale (NRS) score within 24 h postoperatively. The secondary outcomes included pain NRS scores for moving incision, visceral, and rest incision pain at 0-6 h, 6-12 h and 12-24 h; pressure pain threshold and tolerance at 30 min and 24 h postoperatively; PCIA drug consumption, number of compressions, and dosage of rescue analgesics; time to first PCIA compression; serum C-reactive protein (CRP) at 24 h; incidence of drug-related side effects; and rates of anxiety, depression, and sleep disorders on postoperative day 2. RESULTS: Ninety-eight women were randomly included in group E (n = 50) or C (n = 48). Group E showed significantly lower maximum NRS pain scores within 24 h (5 [4-5] vs. 6 [5-6], P < 0.0001) and relieved rest incision, visceral, and moving incision pain at all time points. The PCIA compression was significantly delayed and CRP levels, as well as the incidence of postoperative depression, anxiety, and sleep disorders, were lower in group E. There were no statistically significant differences in hyperalgesia or side effects between the groups. CONCLUSION: Intravenous esketamine could effectively reduce postoperative pain, psychological disorders, and inflammation after CS. This study was registered in the Chinese Clinical Trial Registry with registration number ChiCTR2300078310.